Ian Hickson
Impact in
- Oncology top 0.5%
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
- Molecular Biology top 1%
- DNA Repair Mechanisms
- CRISPR and Genetic Engineering
- Cancer therapeutics and mechanisms
Papers in
-
- Carcinogens and Genotoxicity Assessment 4
- Cancer, Lipids, and Metabolism 3
-
- DNA Repair Mechanisms 14
- Ubiquitin and proteasome pathways 4
- Histone Deacetylase Inhibitors Research 3
- Genomics and Chromatin Dynamics 3
- Co-authors
- Graeme C.M. SmithNiall M.B. MartinStephen P. JacksonHannah FarmerChristopher J. LordDamian A. JohnsonAndrew TuttCharlotte Knights
- Journals
- Cancer Research (3 papers)Journal of Medicinal Chemistry (3 papers)Gene Therapy (2 papers)Molecular Cancer Therapeutics (1 paper)Scientific Reports (1 paper)
- Partner nations
- United KingdomUnited StatesBelgium
In The Last Decade
Ian Hickson
28 papers receiving 6.3k citations
Hit Papers
Peers
Comparison fields: 5 of 107
- Oncology 4.2k
- Molecular Biology 4.8k
- Cancer Research 1.0k
- Reproductive Medicine 456
- Genetics 996
Countries citing papers authored by Ian Hickson
This map shows the geographic impact of Ian Hickson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian Hickson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian Hickson more than expected).
Fields of papers citing papers by Ian Hickson
This network shows the impact of papers produced by Ian Hickson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian Hickson. The network helps show where Ian Hickson may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ian Hickson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 3 | |
| 2 | 2022 | 29 | |
| 3 | 2022 | 15 | |
| 4 | 2021 | 5 | |
| 5 | 2021 | 22 | |
| 6 | 2018 | 10 | |
| 7 | 2016 | 7 | |
| 8 | 2014 | 27 | |
| 9 | 2014 | 41 | |
| 10 | 2013 | 169 | |
| 11 | Discovery of ML216, a Small Molecule Inhibitor of Bloom (BLM) Helicase | 2013 | 6 |
| 12 | 2009 | 51 | |
| 13 | Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Hit paper breakdown → | 2005 | 4751 |
| 14 | Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM Hit paper breakdown → | 2004 | 983 |
| 15 | 1999 | 18 | |
| 16 | 1998 | 27 | |
| 17 | 1998 | 38 | |
| 18 | 1997 | 8 | |
| 19 | 1997 | 51 | |
| 20 | 1996 | 29 |
About Ian Hickson
Ian Hickson is a scholar working on Cancer Research, Molecular Biology, Oncology, Pulmonary and Respiratory Medicine and Genetics, having authored 28 papers that have together received 6.4k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (14 papers), Prostate Cancer Treatment and Research (5 papers), Carcinogens and Genotoxicity Assessment (4 papers), Ubiquitin and proteasome pathways (4 papers), Cancer-related Molecular Pathways (4 papers), Cancer, Lipids, and Metabolism (3 papers), Histone Deacetylase Inhibitors Research (3 papers) and Genomics and Chromatin Dynamics (3 papers). The work is most often cited by research in Oncology (4.2k citations), Molecular Biology (4.8k citations), Cancer Research (1.0k citations), Reproductive Medicine (456 citations) and Genetics (996 citations). Ian Hickson has collaborated with scholars based in United Kingdom, United States and Belgium. Frequent co-authors include Graeme C.M. Smith, Niall M.B. Martin, Stephen P. Jackson, Hannah Farmer, Christopher J. Lord, Damian A. Johnson, Andrew Tutt, Charlotte Knights, Alan Ashworth and Nuala McCabe. Their work appears in journals such as Cancer Research, Journal of Medicinal Chemistry, Gene Therapy, Molecular Cancer Therapeutics and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.